Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Immix Biopharma, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q4 2024
- Shares held
- 2.92M
- +47.5K (+1.7%) vs. Q4 2024
- Total value
- $4.90M
- −$1.41M (−22.4%) vs. Q4 2024
- New holders
- 3
- 4 more added
- Sold out
- 4
- 8 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMMX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 109 | $579.6M |
| Q1 2026 | 77 | $246.6M |
| Q4 2025 | 67 | $127.5M |
| Q3 2025 | 31 | $5.78M |
| Q2 2025 | 23 | $4.68M |
| Q1 2025 | 22 | $4.90M |
| Q4 2024 | 23 | $6.32M |
| Q3 2024 | 25 | $6.10M |
| Q2 2024 | 31 | $8.77M |
| Q1 2024 | 35 | $15.7M |
| Q4 2023 | 28 | $5.32M |
| Q3 2023 | 16 | $1.39M |
| Q2 2023 | 18 | $1.75M |
| Q1 2023 | 12 | $729.8K |
| Q4 2022 | 18 | $1.01M |
| Q3 2022 | 12 | $406.0K |
| Q2 2022 | 7 | $475.0K |
| Q1 2022 | 8 | $352.0K |
| Q4 2021 | 11 | $5.47M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Immix Biopharma, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 35 | $59 | 0.00% | −3−7.9% | Reduced |
| Northwestern Mutual Wealth Management Co | 80 | $134 | 0.00% | +80 | New |
| Bank of America Corp | 120 | $202 | 0.00% | +6+5.3% | Added |
| Wells Fargo & Company | 330 | $554 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 471 | $791 | 0.00% | +290+160.2% | Added |
| UBS Group AG | 10,121 | $17.0K | 0.00% | −4,087−28.8% | Reduced |
| FNY Investment Advisers, LLC | 11,250 | $18.0K | 0.01% | −17,500−60.9% | Reduced |
| BlackRock, Inc. | 11,824 | $19.9K | 0.00% | −2,252−16.0% | Reduced |
| Colony Group, LLC | 11,900 | $20.0K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 12,833 | $21.6K | 0.00% | +12,833 | New |
| Commonwealth Equity Services, LLC | 17,040 | $29.0K | 0.00% | −8,820−34.1% | Reduced |
| SBI Securities Co., Ltd. | 17,500 | $29.4K | 0.00% | 00.0% | Unchanged |
| Tocqueville Asset Management L.P. | 29,300 | $49.2K | 0.00% | −9,000−23.5% | Reduced |
| Private Advisor Group, LLC | 31,225 | $52.5K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 42,960 | $72.2K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 55,262 | $92.8K | 0.00% | +55,262 | New |
| Morgan Stanley | 82,292 | $138.3K | 0.00% | −8,759−9.6% | Reduced |
| Northern Trust Corp | 95,262 | $160.0K | 0.00% | +56,348+144.8% | Added |
| Geode Capital Management, LLC | 160,742 | $270.1K | 0.00% | +10,660+7.1% | Added |
| Vanguard Group Inc | 698,537 | $1.17M | 0.00% | 00.0% | Unchanged |
| Cable Car Capital LLC | 779,358 | $1.31M | 1.49% | −16,742−2.1% | Reduced |
| Bleichroeder LP | 850,000 | $1.43M | 0.38% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −17,523−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Tortoise Investment Management, LLC | 0 | $0 | 0.00% | −1,300−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |